Alglucerase (Ceredase) was a version of glucocerebrosidase that was harvested from human placentaltissue and then modified with enzymes. It was approved by the FDA in 1991 and has been withdrawn from the market due to the approval of similar drugs made with recombinant DNA technology instead of being harvested from tissue; drugs made recombinantly, since there is no concern about diseases being transmitted from the tissue used in harvesting, and are less expensive to manufacture.
Recombinant glucocerebrosidases used as drugs include:
^Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (January 2004). "Glucocerebrosidase mutations in subjects with parkinsonism". Molecular Genetics and Metabolism81 (1): 70–3. doi:10.1016/j.ymgme.2003.11.004. PMID14728994.
^Grabowski GA (2012). "Gaucher disease and other storage disorders". Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program2012: 13–8. doi:10.1182/asheducation-2012.1.13. PMID23233555.
Caillaud C, Poenaru L (2002). "[Gaucher's and Fabry's diseases: biochemical and genetic aspects]". Journal De La Société De Biologie196 (2): 135–40. PMID12360742.
Fabrega S, Durand P, Mornon JP, Lehn P (2002). "[The active site of human glucocerebrosidase: structural predictions and experimental validations]". Journal De La Société De Biologie196 (2): 151–60. PMID12360744.
Alfonso P, Aznarez S, Giralt M, Pocovi M, Giraldo P (2007). "Mutation analysis and genotype/phenotype relationships of Gaucher disease patients in Spain". Journal of Human Genetics52 (5): 391–6. doi:10.1007/s10038-007-0135-4. PMID17427031.